

Literaturverzeichnis

Hamburger Ärzteblatt 12 | 2025

Seite 1

Weidestr. 122 b

22083 Hamburg

Redaktion

E-Mail: verlag@aekeh.de

Tel.: (040) 20 22 99 – 205

Fax: (040) 20 22 99 – 400

S. 12 – 17: Urothelkarzinom der Harnblase – multimodales Management.

Von Prof. Dr. Michael Rink

1. Krebsregisterdaten RKI-Zf. Krebs in Deutschland für 2019/2020. 2023;14. Auflage.
2. Heijden van den AG, Bruins HM, Carrion A, Cathomas R, Compérat EM, Dimitropoulos K et al. EAU Guidelines on Muscle-invasive and Metastatic Bladder Cancer. Edn presented at the EAU Annual Congress Madrid 2025 ISBN 978-94-92671-29-5. 2025.
3. Panebianco V, Narumi Y, Altun E, Bochner BH, Efstathiou JA, Hafeez S et al. Multiparametric Magnetic Resonance Imaging for Bladder Cancer: Development of VI-RADS (Vesical Imaging-Reporting And Data System). *Eur Urol.* 2018;74:294-306.
4. Stein JP, Lieskovsky G, Cote R, Groshen S, Feng A-C, Boyd S et al. Radical Cystectomy in the Treatment of Invasive Bladder Cancer: Long-Term Results in 1,054 Patients. *Journal of Clinical Oncology.* 2001;19:666-75.
5. Russell B, Liedberg F, Khan MS, Nair R, Thurairaja R, Malde S et al. A Systematic Review and Meta-analysis of Delay in Radical Cystectomy and the Effect on Survival in Bladder Cancer Patients. *Eur Urol Oncol.* 2020;3:239-49.
6. Fahmy O, Khairul-Asri MG, Schubert T, Renninger M, Stenzl A, Gakis G. Clinicopathological Features and Prognostic Value of Incidental Prostatic Adenocarcinoma in Radical Cystoprostatectomy Specimens: A Systematic Review and Meta-Analysis of 13,140 Patients. *J Urol.* 2017;197:385-90.
7. Rink M, Shariat SF, Xylinas E, Fitzgerald JP, Hansen J, Green DA et al. Does increasing the nodal yield improve outcomes in patients without nodal metastasis at radical cystectomy? *World J Urol.* 2012;30:807-14.
8. Dorin RP, Daneshmand S, Eisenberg MS, Chandrasoma S, Cai J, Miranda G et al. Lymph node dissection technique is more important than lymph node count in identifying nodal metastases in radical cystectomy patients: a comparative mapping study. *Eur Urol.* 2011;60:946-52.
9. Rink M, Hansen J, Cha EK, Green DA, Babjuk M, Svatek RS et al. Outcomes and prognostic factors in patients with a single lymph node metastasis at time of radical cystectomy. *BJU Int.* 2013;111:74-84.
10. Khetrapal P, Wong JKL, Tan WP, Rupasinghe T, Tan WS, Williams SB et al. Robot-assisted Radical Cystectomy Versus Open Radical Cystectomy: A Systematic Review and Meta-analysis of Perioperative, Oncological, and Quality of Life Outcomes Using Randomized Controlled Trials. *Eur Urol.* 2023;84:393-405.
11. Ditonno F, Veccia A, Montanaro F, Pettenuzzo G, Franco A, Manfredi C et al. Trimodal therapy vs radical cystectomy in patients with muscle-invasive bladder cancer: a systematic review and meta-analysis of comparative studies. *BJU Int.* 2024;134:684-95.
12. Vashistha V, Wang H, Mazzone A, Liss MA, Svatek RS, Schleicher M et al. Radical Cystectomy Compared to Combined Modality Treatment for Muscle-Invasive Bladder Cancer: A Systematic Review and Meta-Analysis. *Int J Radiat Oncol Biol Phys.* 2017;97:1002-20.
13. Seisen T, Sun M, Lipsitz SR, Abdollah F, Leow JJ, Menon M et al. Comparative Effectiveness of Trimodal Therapy Versus Radical Cystectomy for Localized Muscle-invasive Urothelial Carcinoma of the Bladder. *Eur Urol.* 2017;72:483-7.
14. Huddart RA, Hall E, Lewis R, Birtle A, Group STM. Life and death of spare (selective bladder preservation against radical excision): reflections on why the spare trial closed. *BJU Int.* 2010;106:753-5.
15. Pfail JL, Audenet F, Sfakianos JP. Survival of Patients with Muscle-Invasive Urothelial Cancer of the Bladder with Residual Disease at Time of Cystectomy: A Comparative Survival Analysis of Treatment Modalities in the National Cancer Database. *Bladder Cancer.* 2020;6:265-76.

Literaturverzeichnis

Hamburger Ärzteblatt 12 | 2025

Seite 2

Weidestr. 122 b

22083 Hamburg

Redaktion

E-Mail: verlag@aekhh.de

Tel.: (040) 20 22 99 – 205

Fax: (040) 20 22 99 – 400

16. Ohlmann CH, Kerkmann M, Holtmann L, Gschwend JE, Retz M, de Wit M. Quality assurance for the treatment of muscle-invasive and metastasized bladder carcinoma in Germany : An initiative of the Working Groups Urological Oncology (AUO) and Internal Oncology (AIO) in the German Cancer Society (DKG)]. *Urologie*. 2022;61:1351-64.
17. Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft DK A. S3-Leitlinie Früherkennung, Diagnose, Therapie und Nachsorge des Harnblasenkarzinoms. 2025;V 3.0.
18. Boeri L, Soligo M, Frank I, Boorjian SA, Thompson RH, Tollefson M et al. Delaying Radical Cystectomy After Neoadjuvant Chemotherapy for Muscle-invasive Bladder Cancer is Associated with Adverse Survival Outcomes. *Eur Urol Oncol*. 2019;2:390-6.
19. Grossman HB, Natale RB, Tangen CM, Speights VO, Vogelzang NJ, Trump DL et al. Neoadjuvant Chemotherapy plus Cystectomy Compared with Cystectomy Alone for Locally Advanced Bladder Cancer. *New England Journal of Medicine*. 2003;349:859-66.
20. Becker REN, Meyer AR, Brant A, Reese AC, Biles MJ, Harris KT et al. Clinical Restaging and Tumor Sequencing are Inaccurate Indicators of Response to Neoadjuvant Chemotherapy for Muscle-invasive Bladder Cancer. *Eur Urol*. 2021;79:364-71.
21. Pfister C, Gravis G, Flechon A, Chevreau C, Mahammedi H, Laguerre B et al. Perioperative dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin in muscle-invasive bladder cancer (VESPER): survival endpoints at 5 years in an open-label, randomised, phase 3 study. *Lancet Oncol*. 2024;25:255-64.
22. Necchi A, Anichini A, Raggi D, Briganti A, Massa S, Luciano R et al. Pembrolizumab as Neoadjuvant Therapy Before Radical Cystectomy in Patients With Muscle-Invasive Urothelial Bladder Carcinoma (PURE-01): An Open-Label, Single-Arm, Phase II Study. *J Clin Oncol*. 2018;36:3353-60.
23. Powles T, Kockx M, Rodriguez-Vida A, Duran I, Crabb SJ, Van Der Heijden MS et al. Clinical efficacy and biomarker analysis of neoadjuvant atezolizumab in operable urothelial carcinoma in the ABACUS trial. *Nat Med*. 2019;25:1706-14.
24. Shariat SF, Karakiewicz PI, Palapattu GS, Lotan Y, Rogers CG, Amiel GE et al. Outcomes of radical cystectomy for transitional cell carcinoma of the bladder: a contemporary series from the Bladder Cancer Research Consortium. *J Urol*. 2006;176:2414-22; discussion 22.
25. Bajorin DF, Witjes JA, Gschwend JE, Schenker M, Valderrama BP, Tomita Y et al. Adjuvant Nivolumab versus Placebo in Muscle-Invasive Urothelial Carcinoma. *N Engl J Med*. 2021;384:2102-14.
26. Galsky MD, Witjes JA, Gschwend JE, Milowsky MI, Schenker M, Valderrama BP, et al. Extended follow-up from CheckMate 274 including the first report of overall survival outcomes. *EAU 2024 Congress (Paris, France, April 5-8 2024)*. 2024.
27. Bellmunt J, Hussain M, Gschwend JE, Albers P, Oudard S, Castellano D et al. Adjuvant atezolizumab versus observation in muscle-invasive urothelial carcinoma (IMvigor010): a multicentre, open-label, randomised, phase 3 trial. *Lancet Oncol*. 2021;22:525-37.
28. Powles T, Assaf ZJ, Degaonkar V, Grivas P, Hussain M, Oudard S et al. Updated Overall Survival by Circulating Tumor DNA Status from the Phase 3 IMvigor010 Trial: Adjuvant Atezolizumab Versus Observation in Muscle-invasive Urothelial Carcinoma. *Eur Urol*. 2024;85:114-22.
29. Apolo AB, Ballman KV, Sonpavde G, Berg S, Kim WY, Parikh R, et al. Adjuvant Pembrolizumab versus Observation in Muscle-Invasive Urothelial Carcinoma. *N Engl J Med*. 2025;392:45-55.
30. Powles T, Catto JWF, Galsky MD, Al-Ahmadie H, Meeks JJ, Nishiyama H et al. Perioperative Durvalumab with Neoadjuvant Chemotherapy in Operable Bladder Cancer. *N Engl J Med*. 2024;391:1773-86.

Literaturverzeichnis

Hamburger Ärzteblatt 12 | 2025

Seite 3

Weidestr. 122 b

22083 Hamburg

Redaktion

E-Mail: verlag@aekhh.de

Tel.: (040) 20 22 99 – 205

Fax: (040) 20 22 99 – 400

31. Powles T, Valderrama BP, Gupta S, Bedke J, Kikuchi E, Hoffman-Censits J et al. Enfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial Cancer. *N Engl J Med.* 2024;390:875-88.
32. Gontero P, Pisano F, Palou J, Joniau S, Albersen M, Colombo R et al. Complication rate after cystectomy following pelvic radiotherapy: an international, multicenter, retrospective series of 682 cases. *World J Urol.* 2020;38:1959-68.
33. Iwata T, Kimura S, Abufaraj M, Janisch F, Karakiewicz PI, Seebacher V et al. The role of adjuvant radiotherapy after surgery for upper and lower urinary tract urothelial carcinoma: A systematic review. *Urol Oncol.* 2019;37:659-71.

Angaben zu möglichen Interessenkonflikten: vorhanden.

Berater-/Gutachter-/Vortragstätigkeit für AstraZeneca, BMS, MSD und Olympus.

S. 26 – 27: Der lange Weg zur besseren Versorgung.

Von *Sandra Wilsdorf*

1. Hassler M. Menschen mit geistigen und mehrfachen Behinderungen als vulnerable Bevölkerungsgruppe in gesundheitlicher Versorgung. *Deutsche Medizinische Wochenschrift.* 2014;40:139.

S. 32 – 34: Seltene Manifestationen von Karotisstenosen – zwei Fälle.

Von *Dr. Hanna Schlichting, Dr. Haiko Kazarians, Prof. Dr. Dr. Lars Marquardt, Dr. Tobias Ahrens, Dr. Christian-Thiel, PD Dr. Franziska Heidemann, PD Dr. Christian-Alexander Behrendt*

1. Behrendt CA, Thomalla G, Rimmel DL, Petersen EL, Twerenbold R, Debus ES, Kölbl T, Blankenberg S, Schmidt-Lauber C, Peters F, Zyriax BC. Editor's Choice - Prevalence of Peripheral Arterial Disease, Abdominal Aortic Aneurysm, and Risk Factors in the Hamburg City Health Study: A Cross Sectional Analysis. *Eur J Vasc Endovasc Surg.* 2023 Apr;65(4):590-598.
2. Song P, Fang Z, Wang H, Cai Y, Rahimi K, Zhu Y, Fowkes FGR, Fowkes FJI, Rudan I. Global and regional prevalence, burden, and risk factors for carotid atherosclerosis: a systematic review, meta-analysis, and modelling study. *Lancet Glob Health.* 2020;8(5):e721-e729.
3. Zimmermann M, Larena-Avellaneda A, Rother U, Lareyre F, Søgaard M, Tulamo R et al. Editor's Choice - Long Term Outcomes After Invasive Treatment of Carotid Artery Stenosis: a Longitudinal Study of German Health Insurance Claims. *Eur J Vasc Endovasc Surg.* 2023;66(4):493-500.
4. S3-Leitlinie zur Diagnostik, Therapie und Nachsorge der extracraniellen Carotisstenose Langfassung 2. Auflage 03. Februar 2020 AWMF-Registernummer: 004-028 (abgelaufen)
5. Naylor R, Rantner B, Ancetti S, de Borst GJ, De Carlo M, Halliday A et al. Editor's Choice - European Society for Vascular Surgery (ESVS) 2023 Clinical Practice Guidelines on the Management of Atherosclerotic Carotid and Vertebral Artery Disease. *Eur J Vasc Endovasc Surg.* 2023 Jan;65(1):7-111.

Angaben zu möglichen Interessenkonflikten: keine

S. 35: Bilder aus der klinischen Medizin: Stentfrakturen in der Arteria iliaca externas.

Von *Erwin See, Dr. Ralf Weser*

1. Higashiura W, Kubota Y, Sakaguchi S, Kurumatani N, Nakamae M, Nishimine K, Kichikawa K. Prevalence, factors, and clinical impact of self-expanding stent fractures following iliac artery stenting. *J Vasc Surg.* 2009 Mar;49(3):645-52. doi: 10.1016/j.jvs.2008.10.019. PMID: 19268770.